PriceTargets.com logo

Radiopharm Theranostics - RADX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.33
  • Forecasted Upside: 212.27%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$4.59 As of 12/4/2025 05:00 PM ET
▲ +0.1 (2.23%)

This chart shows the closing price for RADX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Radiopharm Theranostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RADX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RADX

Analyst Price Target is $14.33
▲ +212.27% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Radiopharm Theranostics in the last 3 months. The average price target is $14.33, with a high forecast of $18.00 and a low forecast of $12.00. The average price target represents a 212.27% upside from the last price of $4.59.

This chart shows the closing price for RADX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Radiopharm Theranostics. This rating has held steady since September 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/26/2025B. RileyLower TargetBuy ➝ Buy$15.00 ➝ $13.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/21/2025Brookline Capital ManagementInitiated CoverageBuy$18.00
5/12/2025ThinkEquityUpgradeStrong-Buy
5/1/2025Maxim GroupInitiated CoverageBuy$12.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Radiopharm Theranostics logo
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
Read More

Today's Range

Now: $4.59
Low: $4.38
High: $4.85

50 Day Range

MA: $5.43
Low: $4.23
High: $7.54

52 Week Range

Now: $4.59
Low: $3.50
High: $50.82

Volume

4,617 shs

Average Volume

15,634 shs

Market Capitalization

$42.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Radiopharm Theranostics?

The following sell-side analysts have issued stock ratings on Radiopharm Theranostics in the last twelve months: B. Riley, Brookline Capital Management, Maxim Group, ThinkEquity, and Weiss Ratings.
View the latest analyst ratings for RADX.

What is the current price target for Radiopharm Theranostics?

0 Wall Street analysts have set twelve-month price targets for Radiopharm Theranostics in the last year. Their average twelve-month price target is $14.33, suggesting a possible upside of 212.3%. Brookline Capital Management has the highest price target set, predicting RADX will reach $18.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $12.00 for Radiopharm Theranostics in the next year.
View the latest price targets for RADX.

What is the current consensus analyst rating for Radiopharm Theranostics?

Radiopharm Theranostics currently has 1 sell rating, 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RADX will outperform the market and that investors should add to their positions of Radiopharm Theranostics.
View the latest ratings for RADX.

What other companies compete with Radiopharm Theranostics?

Other companies that are similar to Radiopharm Theranostics include Molecular Partners, Actuate Therapeutics, Coherus Oncology, Connect Biopharma and Cardiff Oncology. Learn More about companies similar to Radiopharm Theranostics.

How do I contact Radiopharm Theranostics' investor relations team?

Radiopharm Theranostics' physical mailing address is LEVEL 3 62 LYGON STREET, CARLTON VIC, C3 3053, AU. The company's listed phone number is 61-3-9824-5254. The official website for Radiopharm Theranostics is www.radiopharmtheranostics.com. Learn More about contacing Radiopharm Theranostics investor relations.